Roche Buys US Firm 89Bio For Up To $3.5 Billion

2025-09-18 02:15:39

(MENAFN- Swissinfo) Swiss pharma giant Roche is acquiring the California-based liver and cardiovascular disorders specialist 89bio for an initial sum of $2.4 billion (CHF1.9 billion). The Basel-based pharmaceutical giant expects to make additional payments of up to $1.1 billion. This content was published on September 18, 2025 - 10:15 2 minutes Keystone-SDA

Français fr Roche s'offre le californien 89bio pour jusqu'à 3,5 milliards Original Read more: Roche s'offre le californien 89bio pour jusqu'à 3,5 milliard

+Get the most important news from Switzerland in your inbox

In particular, the deal enables the Basel-based multinational to get its hands on pegozafermin, which is currently being evaluated by 89bio in a phase III clinical study for the treatment of hepatic steatosis linked to metabolic dysfunction, the two companies said in press releases on Thursday.

The initial offer of $6 per share represents a premium of 52% over the weighted average price of 89bio over the last 60 trading days up to September 17, Roche said. The amount offered exceeds 89bio's closing price on that date by 79%, notes 89bio.

More More Drug pricing Potential US tariff exemption for Swiss pharma is not necessarily a boon

This content was published on Jul 22, 2025 Donald Trump is pressuring the pharma industry with tariffs. But experts say that tariffs will have less impact on the industry than pricing.

Read more: Potential US tariff exemption for Swiss pharma is not necessarily a boo

MENAFN18092025000210011054ID1110081206

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.